109 results about "Hypertrophic scar" patented technology

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and/or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.

The present invention provides a method for treating or preventing excessive scarring, including keloid and hypertrophic scars, by administering 4-hydroxy tamoxifen to a patient with excessive scarring or a wound at risk for developing excessive scarring.

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

A method for treating a scar on a skin surface of a subject is provided. A subject is identified as having a skin surface with scar tissue. In response to identifying the subject as having the scar tissue, a housing comprising at least one acoustic transducer is placed on the skin surface with the scar tissue and the acoustic transducer is activated to apply high intensity focused ultrasound energy to a portion of the scar tissue. Other embodiments are also described.

A method of treating keloid scars, hypertrophic scars or burn scars with contracture includes administering low molecular weight hyaluronic acid to the keloid scar, hypertrophic scar or burn scar with contracture.

The invention provides a liposome gel preparation for treating hypertrophic scars. The liposome gel preparation comprises liposome, gel material and glycerol, wherein the liposome is encapsulated with paeonol, and the surface of the liposome is bonded with vascular endothelial growth factor (VEGF) antibodies through polyethylene glycol. The invention provides a preparation method and application of the gel preparation at the same time. The gel preparation is encapsulated by using a material such as phospholipid with good physiological compatibility with the human body, so that the problems of poor water solubility and low stability of the paeonol are effectively solved. The VEGF antibodies are used for modifying the surface of the liposome, lipid particles enter the dermis through the epidermis by using the permeation promoting effect of liposome carriers and are directionally bonded with VEGF receptors of the pathological change skin part, and the encapsulated medicament is released at the same time, so that positioned retention of the medicament in the scar hyperplasia part is realized. Compared with other reported scar hyperplasia resistant medicament preparations or treatment schemes, the invention has the advantages that the liposome gel preparation is low in relapse rate, reduces the occurrence rate of the toxic or side effect and can be applied to any scar hyperplasia part of the body.

An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. Halofuginone can reduce or eliminate clinical symptoms of these disorders, as well as substantially prevent the formation of keloids and hypertrophic scars.

The invention provides a microneedle patch for scar treatment and a preparation method thereof, the microneedle patch comprises a substrate and a needle body arranged on the surface of the substrate, the needle body comprises an anti-scar active component and a matrix material, the anti-scar active component comprises onion extract, cannabis sativa leaf extract, allantoin and heparin sodium in a mass ratio of 1: (0-1): (0-0.5): (0-0.02); the anti-scar active component mainly comprises an onion extract, the substrate also comprises a matrix material, and the matrix material comprises but not limited to hyaluronic acid, sodium hyaluronate, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, sodium carboxymethyl cellulose, hydroxypropyl-beta-cyclodextrin, sodium alginate, polylactic acid, chitosan and glucan; the microneedle patch for scar treatment has certain mechanical strength, is convenient to use and good in stability, can realize minimally invasive painless effect when acting on skin, and provides a new and effective method for treatment of hypertrophic scars at any part of a body.

The invention relates to a siRNA molecular composition and application thereof in treatment on hypertrophic scars and keloids. The siRNA molecular composition contains siRNA molecules with the sequence of 5'-CCCAAGGGCUACCAUGCCAACUUCU-3' and siRNA molecules with the sequence of 5'-GGUCUGGUGCCUGGUCUGAUGAUGU-3'. The siRNA molecular composition is proved to be capable of promoting in-vitro fibroblast apoptosis of the hypertrophic scars and keloids and have a good treatment effect on the hypertrophic scars in an animal model.

The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the Bcl-2/Bcl-XL family of anti-apoptotic proteins for the treatment of cutaneous wounds, burns and abrasions during the healing phase.

The invention relates to the new applications of integrin beta 4 binding protein (ITGB4BP) and derivates thereof, or gene recombinant expression vector expressing the ITGB4BP or derivates thereof in preventing and/or treating hypertrophic scar or fibrosis lesion; wherein, the amino acid sequence of the ITGB4GB is SEQ ID NO 1; the derivates of the ITGB4BP are protein derivates retaining the combining site and the functional site of the ITGB4BP (SEQ ID NO 1). The application is realized by applying the ITGB4BP or derivates thereof, or gene recombinant expression vector expressing the ITGB4BP orderivates thereof, or the drug combination or the kit of the invention on subjects with an effective dose in treatment. The drug combination or the kit contains the ITGB4BP or derivates thereof, or gene recombinant expression vector expressing the ITGB4BP or derivates thereof and an officinal excipient or vectors and the like with an effective dose in treatment. Preferably, the subjects are humanbeings or animals.

The invention relates to the technical field of external medicines for hypertrophic scars, and particularly relates to a preparation method and an application of capsaicin-collagen sponge. The preparation method comprises the following steps: 1 preparing collagen powder from tendo calcaneus; 2 extracting the collagen powder with pepsin, so as to obtain an extract liquid; 3 centrifugally collecting supernate; 4 separating out collagen by adding sodium hydroxide, and washing, so as to prepare high-purity collagen; 5 redissolving the collagen with ethylic acid; and 6 evenly mixing the collagen liquid, glycerinum and capsaicin, and then carrying out freeze-drying, so as to obtain the capsaicin-collagen sponge. The capsaicin-collagen sponge prepared by the method is applied to tissue trauma repair and inhibition of the hypertrophic scars in the tissue trauma repair process, and has the advantage of good percutaneous permeability; the drug liver first-pass effect can be avoided; and the thrill to the skin can be reduced.

The invention belongs to the technical field of treating skin scars, and particularly relates to a breathable itching-relieving antisepsis scar treating paster and a preparation method thereof. The technical problem to be solved is to provide a new choice for treating a hypertrophic scar. According to the technical scheme, the breathable itching-relieving antisepsis scar treating paster is prepared from the following active ingredients in percentage by weight: 97.9% of silicone, 1% of mint, 1% of borneol, 0.05% of heparin sodium, and 0.05% of nanosilver. The invention further provides a preparation method for the breathable itching-relieving antisepsis scar treating paster. The treating paster provides a new choice for treating the scar.

The present invention provides methods for treating and/or limiting fibrotic disorders and/or treating or limiting scars selected from the group consisting of keloids and hypertrophic scars comprising administering to an individual in need thereof an amount effective to treat and/or limit scars selected from the group consisting of keloids and hypertrophic scars of a polypeptide comprising an HSP20- related polypeptide.

Belonging to the field of medical technologies, the invention relates to a prescription and preparation method for topical gel and ointment dosage forms containing tranilast component, and therapeutic effects of the dosage forms in keloid and hypertrophic scar fields. The topical gel and ointment contain tranilast, a cosolvent, a substrate, a humectant, a penetration enhancer, a preservative, a pH regulator, purified water and other ingredients. The preparation method includes the steps of: 1. taking a prescribed amount of the substrate, adding a proper amount of purified water, performing full swelling at 20-80DEG C, adjusting the pH to less than 5, adding a prescribed amount of humectant, and conducting heat preservation to obtain A; 2. taking a prescribed amount of tranilast, the cosolvent, the preservative, and a proper amount of purified water, carrying out heating dissolving at 20-80DEG C, and performing heat preservation to obtain B; and 3. Pouring B into A, conducting heat preservation and swelling, and stirring the mixture evenly, thus obtaining the products. The tranilast gel and ointment provided by the invention have the pharmacological activity of treating hypertrophic scars and keloids.